Fever and the Ageing Immune system, A Review

Year 2023, Volume: 4 Issue: 2, 113 - 120, 28.08.2023

Seema Mahesh , Esther Van Der Werf Mahesh Mallappa George Vithoulkas Nai Ming Lai

https://doi.org/10.53811/ijtcmr.1330957

Abstract

Whether to treat fever in the elderly, is a question that has not yet been answered. This review examines the available evidence so far, to arrive at a comprehensive picture about this question. Aged population are a special category due to their lower basal body temperature, blunted fever response and existing co morbidities. The aging immune system undergoes many changes in all its faculties, which alters its ability to mount an efficient acute inflammatory response. In such a scenario, fever is mostly absent and there is a need to revise the fever criteria in the elderly. Having said that, the most successfully aging, centenarians, mount efficient febrile response during infections, indicating that aging itself may not be the reason for the reduced febrile response. Holistic medicine, such as homeopathy, views the fever scenario differently and advocates interference only when the immune system is helpless. The ‘levels of health theory’ explains that the healthiest benefit from fever while those with reduced immunity suffer from it. This theory may prove to be an invaluable clinical tool to arrive at definite clinical guidelines concerning the treatment of fever, especially in the elderly. However, it requires scientific investigation before it can be used as a clinical tool.
There is no conclusive evidence on whether fever must be treated or not in the elderly and whether holistic medicine may have a solution to this dilemma. This is a research gap that needs to be filled with quality studies in the current health scenario.

Keywords

fever, ageing, elderl, older adults, immunosenescence

References

• 1. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology E-Book. Saintt Louis: Elsevier, 2017.
• 2. Korniluk A, Koper O, Kemona H et al. From inflammation to cancer. Ir. J. Med. Sci. (1971 -)2016;186:57–62.
• 3. Frangogiannis NG. Inflammation in cardiac injury, repair and regeneration. Curr. Opin. Cardiol. 2015;30:240–5.
• 4. Hasday JD, Thompson C, Singh IS. Fever, immunity, and molecular adaptations. Compr. Physiol. 2014;4:109–48.
• 5. Hasday JD, Fairchild KD, Shanholtz C. The role of fever in the infected host. Microbes Infect. 2000;2:1891–904.
• 6. Blomqvist A, Engblom D. Neural Mechanisms of Inflammation-Induced Fever. Neuroscientist 2018;24:381–99.
• 7. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat.Rev. Immunol. 2015;15:335–49.
• 8. Fisher DT, Vardam TD, Muhitch JB et al. Fine-tuning immune surveillance by fever-range thermal stress. Immunol.Res. 2009;46:177–88.
• 9. Lin CD, Zhang YH, Zhang K et al. Fever Promotes T Lymphocyte Trafficking via a Thermal Sensory Pathway Involving Heat Shock Protein 90 and α4 Integrins. Immunity 2019;50:137–51.e6.
• 10. El-Radhi AS. Clinical Manual of Fever in Children. Cham: Springer International Publishing, 2018:179–92.
• 11. Kluger MJ, Ringler DH, Anver MR. Fever and Survival. Science 1975;188:166–8.
• 12. Lee C-T, Zhong L, Mace TA et al. Elevation in Body Temperature to Fever Range Enhances and Prolongs Subsequent Responsiveness of Macrophages to Endotoxin Challenge. PLoS One 2012;7:e30077.
• 13. Jiang Q, Cross AS, Singh IS et al. Febrile Core Temperature Is Essential for Optimal Host Defense in Bacterial Peritonitis. Infect Immun. 2000;68:1265–70.
• 14. Schulman CI, Namias N, Doherty J et al. The Effect of Antipyretic Therapy upon Outcomes in Critically Ill Patients: A Randomized, Prospective Study. Surg Infect. 2005;6:369–75.
• 15. Hobohm U. Fever therapy revisited. Br. J.Cancer 2005;92:421–5.
• 16. Megremi ASF. Is fever a predictive factor in the autism spectrum disorders? Med.Hypotheses 2013;80:391–8.
• 17. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005;6:1191–7.
• 18. Serhan CN. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J. 2017;31:1273–88.
• 19. Headland SE, Norling LV. The resolution of inflammation: Principles and challenges. Semin. Immunol. 2015;27:149–60.
• 20. Lawrence T, Gilroy DW. Chronic inflammation: a failure of resolution? Int. J. Exp. Pathol. 2006;88:85–94.
• 21. Nathan C, Ding A. Nonresolving Inflammation. Cell 2010;140:871–82.
• 22. Chan MM-Y, Moore AR. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immun. 2010;184:6418–26.
• 23. Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat.Rev. Immunol. 2015;16:51–67.
• 24. Boneberg E-M, Hartung T. Febrile Temperatures Attenuate IL-1β Release by Inhibiting Proteolytic Processing of the Proform and Influence Th1/Th2 Balance by Favoring Th2 Cytokines. J. Immun. 2003;171:664–8.
• 25. Vithoulkas G, Carlino S. The “continuum” of a unified theory of diseases. Med. Sci. Monit. 2010;16:15.
• 26. Earn DJD, Andrews PW, Bolker BM. Population-level effects of suppressing fever. Proc. R. Soc. B: Biol. 2014;281:20132570.
• 27. Barnig C, Bezema T, Calder PC et al. Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease. Front.immunol. 2019;10:1699.
• 28. FRANCESCHI CLAUDIO, BONAFÈ MASSIMILIANO, VALENSIN SILVANA et al. Inflamm-aging: An Evolutionary Perspective on Immunosenescence. Ann. N. Y. Acad. Sci. 2006;908:244–54.
• 29. El-Radhi AS. Fever management: Evidence vs current practice. World J. Clin. Pediatr. 2012;1:29–33.
• 30. Carey JV. Literature review: should antipyretic therapies routinely be administered to patient fever? J. Clin. Nurs. 2010;19:2377–93.
• 31. Kiekkas P, Velissaris D, Karanikolas M et al. Peak body temperature predicts mortality in critically ill patients without cerebral damage. Heart & Lung 2010;39:208–16.
• 32. Hew YH, Blebil AQ, Dujaili JA et al. Assessment of knowledge and practices of parents regarding childhood fever management in Kuala Lumpur, Malaysia. Drugs Ther. Perspect. 2018;35:29–35.
• 33. Circiumaru B, Baldock G, Cohen J. A prospective study of fever in the intensive care unit. Intensive Care Med. 1999;25:668–73.
• 34. Laupland KB, Shahpori R, Kirkpatrick AW et al. Occurrence and outcome of fever in critically ill adults. Crit. Care Med. 2008;36:1531–5.
• 35. Donoso A, Arriaga D. Fever and antipyretic therapy in the septic patient in the intensive care unit: an update. Bol. Med. Hosp. Infant. Mex. (English Edition) 2019;75,
• 36. Lee J-C, Cia C-T, Lee N-Y et al. Causes of death among dengue patients causes of death among hospitalized adults with dengue fever in Tainan, 2015: Emphasis on cardiac events and bacterial infections. J. Microbiol. Immunol. Infect. 2022;55:207–14.
• 37. Rice P, Martin E, He J-R et al. Febrile-Range Hyperthermia Augments Neutrophil Accumulation and Enhances Lung Injury in Experimental Gram-Negative Bacterial Pneumonia. J. Immun. 2005;174:3676–85.
• 38. Walter EJ, Hanna-Jumma S, Carraretto M et al. The pathophysiological basis and consequences of fever. Crit. Care 2016;20,
• 39. Barie PS, Hydo LJ, Eachempati SR. Causes and Consequences of Fever Complicating Critical Surgical Illness. Surg. Infect. 2004;5:145–59.
• 40. Chan PS, Berg RA, Tang Y et al. Association Between Therapeutic Hypothermia and Survival After In-Hospital Cardiac Arrest. JAMA 2016;316:1375–82.
• 41. Kurisu K, Yenari MA. Therapeutic hypothermia for ischemic stroke; pathophysiology and future promise. Neuropharmacology 2018;134:302–9.
• 42. Liu E, Lewis K, Al-Saffar H et al. Naturally occurring hypothermia is more advantageous than fever in severe forms of lipopolysaccharide- and Escherichia coli-induced systemic inflammation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012;302:R1372–R1383.
• 43. Bhavani SV, Carey KA, Gilbert ER et al. Identifying Novel Sepsis Subphenotypes Using Temperature Trajectories. Am. J. Resp. Crit. Care Med. 2019;200:327–35.
• 44. Caruso C, Buffa S, Candore G et al. Mechanisms of immunosenescence. Immun. Ageing 2009;6,
• 45. Doyle JF, Schortgen F. Should we treat pyrexia? And how do we do it? Crit. Care 2016;20:303.
• 46. Niven DJ, Laupland KB. Pharmacotherapy of fever control among hospitalized adult patients. Expert Opin Pharmacother 2013;14:735–45.
• 47. Vitale B. Holistic Approach to the Immunobiology of Aging (view on the turn of millenium). Acta Clin.Croat. 2019,
• 48. Zainabadi K. A brief history of modern aging research. Exp.Gerontol. 2018;104:35–42.
• 49. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat.Rev. Cardiol. 2018;15:505–22.
• 50. Franceschi C, Campisi J. Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. J. Gerontol. - Biol. Sci. Med. Sci. 2014;69:S4–S9.
• 51. Skwarło-Sońta K. Functional connections between the pineal gland and immune system. Acta Neurobiol. Exp. (Wars) 1996;56:341–57.
• 52. Jenny NS. Inflammation in aging: cause, effect, or both? Discov. Med. 2012;13:451–60.
• 53. Meftahi GH, Jangravi Z, Sahraei H et al. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging.” Inflamm. Res. 2020;69:825–39.
• 54. Perrotta F, Corbi G, Mazzeo G et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging clin. exp. res. 2020;32:1599–608.
• 55. Ginaldi L, Loreto MF, Corsi MP et al. Immunosenescence and infectious diseases. Microbes Infect. 2001;3:851–7.
• 56. Dunn RM, Busse PJ, Wechsler ME. Asthma in the elderly and late-onset adult asthma. Allergy 2017;73:284–94.
• 57. MILLER R. Aging and immune function: Cellular and biochemical analyses. Exp.Gerontol. 1994;29:21–35.
• 58. Cossarizza A, Ortolani C, Monti D et al. Cytometric analysis of immunosenescence. Cytometry 1997;27:297–313.
• 59. Waalen J, Buxbaum JN. Is Older Colder or Colder Older? The Association of Age With Body Temperature in 18,630 Individuals. J. Gerontol. - Biol. Sci. Med. Sci.2011;66A:487–92.
• 60. Roghmann M-C, Mackowiak PA, Warner J. The Relationship between Age and Fever Magnitude. Am. J. Med. Sci. 2001;322:68–70.
• 61. Turkulov V, Brkic S, Sevic S et al. Fever of unknown origin in elderly patients. Srp. Arh. Za Celok. Lek 2011;139:64–8.
• 62. Norman DC. Fever in the Elderly. Clin. Infect. Dis. 2000;31:148–51.
• 63. Cristofaro PA. Infection and Fever in the Elderly. J. Am. Podiatr. Med. Ass. 2004;94:126–34.
• 64. Guzmán MG, Kouri G, Bravo J et al. Effect of age on outcome of secondary dengue 2 infections. Int. J. Infect. Dis. 2002;6:118–24.
• 65. Wiewel MA, Harmon MB, van Vught LA et al. Risk factors, host response and outcome of hypothermic sepsis. Crit. Care 2016;20:328.
• 66. AHKEE SUNKET, SRINATH LATHA, RAMIREZ JULIO. Community-Acquired Pneumonia in the Elderly: Association of Mortality With Lack of Fever and Leukocytosis. South. Med. J. 1997;90:296–8.
• 67. Zhang Z, Chen L, Ni H. Antipyretic Therapy in Critically Ill Patients with Sepsis: An Interaction with Body Temperature. PLoS One 2015;10:e0121919.
• 68. Lin RJ, Lee TH, Leo YS. Dengue in the elderly: a review. Expert. Rev. Anti. Infect. Ther. 2017;15:729–35.
• 69. Rowe EK, Leo YS, Wong JG et al. Correction: Challenges in Dengue Fever in the Elderly: Atypical Presentation and Risk of Severe Dengue and Hospita-Acquired Infection. PLoS Negl. Trop. Dis. 2014;8:e 2777, corrected: e2886.
• 70. Brody GM. Hyperthermia and Hypothermia in the Elderly. Clin. Geriatr. Med. 1994;10:213–29.
• 71. Tiruvoipati R, Ong K, Gangopadhyay H et al. Hypothermia predicts mortality in critically ill elderly patients with sepsis. BMC Geriatr. 2010;10:70.
• 72. Peres Bota D, Lopes Ferreira F, Mélot C et al. Body temperature alterations in the critically ill. Intensive Care Med. 2004;30:811–6.
• 73. Egi M, Makino S, Mizobuchi S. Management of fever in critically ill patients with infection. J. Emerg. Crit. Care Med. 2018;2:10–.
• 74. Jampel HD, Duff GW, Gershon RK et al. Fever and immunoregulation. III. Hyperthermia augments the primary in vitro humoral immune response. J. Exp. Med. 1983;157:1229–38.
• 75. Sundén-Cullberg J, Rylance R, Svefors J et al. Fever in the Emergency Department Predicts Survival of Patients With Severe Sepsis and Septic Shock Admitted to the ICU*. Crit. Care Med. 2017;45:591–9.
• 76. Rajakariar R. COX-2 in Inflammation and Resolution. Mol.Interv. 2006;6:199–207.
• 77. Veteikis D. Anthropogenic and temporal components in a complex trigger of type 1 diabetes suggest the active participation of antipyretics. Med. Hypotheses 2016;93:126–31.
• 78. Young P, Saxena M, Bellomo R et al. Acetaminophen for Fever in Critically Ill Patients with Suspected Infection. N Engl J Med 2015;373:2215–24.
• 79. Deen J, von Seidlein L. Paracetamol for dengue fever: no benefit and potential harm? Lancet Glob.Health 2019;7:e552–e553.
• 80. Ludwig J, McWhinnie H. Antipyretic drugs in patients with fever and infection: literature review. Br. J. Nurs. 2019;28:610–8.
• 81. Lell B, Sovric M, Schmid D et al. Effect of Antipyretic Drugs in Children with Malaria. Clin. Infect. Dis. 2001;32:838–41.
• 82. Eyers S, Weatherall M, Shirtcliffe P et al. The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analyis. J. R. Soc. Med. 2010;103:403–11.
• 83. Eskilsson A, Matsuwaki T, Shionoya K et al. Immune-Induced Fever Is Dependent on Local But Not Generalized Prostaglandin E(2) Synthesis in the Brain. J. Neurosci. 2017;37:5035–44.
• 84. Hubbard RE, Woodhouse KW. Frailty, inflammation and the elderly. Biogerontology 2010;11:635–41.
• 85. Nikolich-Zugich J, Knox KS, Rios CT et al. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. GeroScience 2020;42:505–14.
• 86. Pence BD. Severe COVID-19 and aging: are monocytes the key? GeroScience 2020;42:1051–61.
• 87. Vithoulkas G. Levels of Health. 3rd ed. Alonissos, Greece: International Academy of Classical Homeopathy, 2019.
• 88. Wrotek S, Sobocińska J, Kozłowski HM, et al. A. New insights into the role of glutathione in the mechanism of fever. Int. J. Mol. Sci.. 2020;19:1393.
• 89. Surana NK, Kasper DL. Approach to the Patient with an Infectious Disease. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. eds. Harrison's Principles of Internal Medicine. 20th ed. McGraw-Hill;2018:Chapter 115. Accessed October 15, 2020. https://accessmedicine.mhmedical.com/content.aspx?bookid=2129&sectionid=192019106